Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Florian Heidel

Professor, Director

Universitätsmedizin Greifswald

Germany

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Cell Biology

30%

Biochemistry

20%

Targeted Therapy

50%

Hematology

40%

Cancer Biology

30%

Hematopoiesis

30%

Multiple Myeloma

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

Functional characterization of histone replacement variant MacroH2A1 (H2afy) in acute myeloid leukemia (AML)

Open Date: 2022-01-01

Close Date:

Grant: Close

Meeting the Challenges of Chronic Age-Related Diseases in Rural Areas

Open Date: 2022-01-01

Close Date:

Grant: Close

Effects of YBX1 on gene expression and translation in acute myeloid leukemia (AML)

Open Date: 2020-01-01

Close Date:

Grant: Close

Mechanistic impact of immunoproteasome function on cell competition in acute myeloid leukemia (AML)

Open Date: 2020-01-01

Close Date:

Grant: Close

Impact of Plcg1 on hematopoietic and leukemia stem cell function

Open Date: 2017-01-01

Close Date:

Articles20

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Article Link

Year:

2025

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms

Article Link

Year:

2025

Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)

Article Link

Year:

2025

Malignant JAK-signaling: at the interface of inflammation and malignant transformation

Article Link

Year:

2025

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Article Link

Year:

2025

Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)

Article Link

Year:

2025

Pomalidomide combinations are a safe and effective option after daratumumab failure

Article Link

Year:

2023

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.

Article Link

Year:

2023

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

Article Link

Year:

2023

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

Article Link

Year:

2023

Aggregates of non-muscular myosin IIA in erythrocytes associate with GATA1- and GFI1B-related thrombocytopenia.

Article Link

Year:

2023

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.

Article Link

Year:

2023

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis

Article Link

Year:

2022

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Article Link

Year:

2022

Breakthrough infections in MPN-COVID vaccinated patients.

Article Link

Year:

2022

Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis.

Article Link

Year:

2022

Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity.

Article Link

Year:

2022

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

Article Link

Year:

2022

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms.

Article Link

Year:

2022

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.

Article Link

Year:

2022

Collaborators20

daniela cilloni

PROFESSOR

University of Turin

ITALY

Alejo Rodriguez-Fraticelli

Research Professor

Instituciò Catalana de Recerca i Estudis Avancats

SPAIN

Elisabetta Abruzzese

UNIVERSITY TOR VERGATA

ITALY

Antonio Cuneo

University of Ferrara

ITALY

Annamaria Brioli

Consultant, Head of the Plasma Cell Dyscrasias and Multiple Myeloma Clinic and Translational Research Program

Medizinische Hochschule Hannover

GERMANY

Francesco Ferracuti

Università Politecnica delle Marche

ITALY

Thomas Stoll

QIMR Berghofer Medical Research Institute

AUSTRALIA

Inken Hilgendorf

Universitätsklinikum Jena

GERMANY

Yee-May Ling

Honorary Senior Lecturer

The University of Queensland

AUSTRALIA

Valerio De Stefano

ITALY

Massimiliano BONIFACIO

University of Verona

ITALY

Steven Lane

LAB HEAD

QIMR Berghofer Medical Research Institute

AUSTRALIA

Mascha Binder

University Hospital Basel

SWITZERLAND

Giuseppe Alberto Maria PALUMBO

Associate Professor of Hematology

Università degli Studi di Napoli Federico II

ITALY

José Rivera

SPAIN

Claudia Bruedigam

QIMR Berghofer Medical Research Institute

AUSTRALIA

Gunter Hartel

Griffith University

AUSTRALIA

Steffen Koschmieder

RWTH Aachen University

GERMANY

Giovanni Caocci

University of Cagliari

ITALY

Gerald de Haan

University Medical Center Groningen

NETHERLANDS

How do I reach out?

Meet Kite AI